AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 262 min read$KYMR

BVF PARTNERS L P/IL sold $5.5M of KYMR (indirect holdings)

BVF PARTNERS L P/IL sold 51,858 indirectly-held shares of Kymera Therapeutics, Inc. (KYMR) at $106.50 ($5.52M total) on 2026-06-26.

Original reporting
SEC EDGAR · BVF PARTNERS L P/IL
Published Jun 26, 2026, 10:48 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 26, 2026, 10:53 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$KYMR
Neutral
low confidence
Mentioned
$KYMR
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$KYMRNeutralLow
01

Why it matters

The newest fact is the same-day open-market sale by a director via an indirect holding, totaling about $5.52M at $106.50/share.

02

Market read

Useful for tracking insider behavior, but it does not introduce new operational/financial guidance or regulatory/clinical catalysts.

03

What to watch

No 10b5-1 plan is stated, but the article also provides no context for why the sale occurred; traders should wait for additional insider buys/sells or company-specific news.

Relevance 6/10Novelty 5/10Timing: filed 2026-06-26 (after-hours) for an insider sale executed the same day

Background

This is an SEC Form 4 insider transaction disclosure for Kymera Therapeutics, Inc.

Company-level read

Ticker impact

$KYMRNeutralLow confidence
Context

Kymera Therapeutics disclosed a Form 4: BVF Partners L P/IL (director) sold 51,858 shares at $106.50 on 2026-06-26 via an open-market sale.

Expected impact

Likely limited, short-lived impact; watch for follow-through in subsequent insider filings rather than a directional move.

Evidence & confidence

Form 4 insider sales can be routine and are not accompanied here by new company fundamentals; the filing provides timing and size but no stated reason or guidance change.

Market effects

Sector

Minimal read-across; this is a single-company insider transaction with no sector-wide catalyst.

Regional

None.

Global

None.

Counterpoint

What could challenge this read

The sale may be unrelated to fundamentals (liquidity/tax/portfolio rebalancing), especially since the filing does not indicate any adverse company event.

Key entities

  • issuer
    Kymera Therapeutics, Inc.

    Subject of the Form 4 insider transaction; director-related indirect holdings were reduced via an open-market sale.

  • insider
    BVF Partners L P/IL

    Reporter on the Form 4; director role and sold 51,858 shares at $106.50 on 2026-06-26.

Read at source← All news

Related articles

AUG 6
$KYMRMed

Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update

Kymera Therapeutics (NASDAQ: KYMR) reported Q2 2026 results and updated its pipeline. Enrollment in KT-621 BROADEN2 Phase 2b atopic dermatitis finished nearly six months early, shifting topline data to year-end 2026 and Phase 3 start to mid-2027. KT-621 asthma data is due late 2027. KT-579 Phase 1 data is expected 4Q26. Cash was $1.5B as of June 30, 2026.

investingnews.com6 min
AUG 5
$KYMRMed

Kymera Therapeutics, Inc. (KYMR): Results of Operations and Financial Condition

Kymera Therapeutics, Inc. (KYMR) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 kymr-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update Enrollment completed in KT-621 (STAT6) BROADEN2 Phase 2b AD trial nearly six months ahead of anticipated timeline, with data e

SEC EDGAR 8-K6 min
JUL 13
$AXPMed

American Express, Biogen upgraded: Wall Street's top analyst calls

Wall Street analysts issued multiple rating changes. JPMorgan raised American Express (AXP) to Overweight, PT $400. Truist upgraded Biogen (BIIB) to Buy, PT $235, citing upcoming Phase 2 and Phase 3 readouts. JPMorgan also raised Keysight (KEYS) to Overweight, PT $400. Other actions included upgrades for Humana (HUM) and downgrades for Papa John’s (PZZA) and Best Buy (BBY).

yahoo.com4 min
JUL 13
$CRCLMed

Here Are Monday’s Best Wall Street Analyst Research Calls: Atmos Energy, Best Buy, Biogen, Capital One, Costco, Disney, Papa John’s International, Shopify, and More

The article lists Monday analyst calls and market moves. It highlights SK hynix’s Nasdaq debut, up about 12.8% to $168.01 after raising nearly $26.5B. It cites upgrades including BIIB to Buy at $235, COF to Buy at $229, and SHOP to Buy at $160, plus downgrades like BBY to Hold. Circle (CRCL) rose ~15% on OCC approval.

yahoo.com6 min